Stage II adenosquamous cell lung cancer represents a challenging diagnosis where cancer cells show both adenocarcinoma and squamous cell features, and the tumor has started to spread within the lung or to nearby lymph nodes—but treatment options including surgery and chemotherapy can still make a meaningful difference in helping patients live longer and manage their disease.

How Treatment Goals Shape Your Care Journey

When you receive a diagnosis of stage II adenosquamous cell lung cancer, the main goal of treatment is to remove the cancer completely and prevent it from coming back. Because the cancer is still considered early stage, doctors have several effective tools at their disposal. Treatment decisions depend heavily on the exact size and location of your tumor, whether cancer has reached the lymph nodes inside your lung, and your overall health condition.^[1]

At stage II, the cancer has grown larger than in stage I or has spread to nearby lymph nodes, but it hasn’t traveled to distant parts of your body. This is important because it means the disease is still potentially curable with the right approach. Standard treatments approved by medical societies worldwide form the foundation of care, but ongoing research into new therapies through clinical trials continues to offer hope for even better outcomes.^[2]

Adenosquamous carcinoma is a rare form of lung cancer, making up only about 2% to 4% of all lung cancer cases. What makes it unique is that when doctors examine the tumor under a microscope, they find two different types of cancer cells mixed together: adenocarcinoma cells and squamous cell carcinoma cells. According to medical definitions, each type must make up at least 10% of the tumor to be classified as adenosquamous carcinoma.^[4]

The complexity of this cancer means that treatment must be carefully planned to address both cell types. Your medical team will consider not just the stage of your cancer but also your ability to tolerate surgery and chemotherapy, any other health conditions you have, and increasingly, the genetic makeup of your tumor cells. This personalized approach helps ensure you receive the most appropriate treatment for your specific situation.^[1]

Standard Treatment Approaches

Surgery as the Primary Treatment

For stage II adenosquamous cell lung cancer, surgery is typically the first and most important treatment. The operation, called a lobectomy, involves removing the entire lobe of the lung where the cancer is located. Your lungs have three lobes on the right side and two on the left, and removing one lobe usually allows the remaining lung tissue to function well enough to support your normal activities.^[6]

During the same operation, the surgeon will also remove lymph nodes from the center of your chest to check whether cancer has spread there. This information is crucial because it helps doctors understand exactly how advanced your cancer is and whether you need additional treatment after surgery. The goal is what doctors call an R0 resection, which means removing all visible cancer with clear margins where no cancer cells are found at the edges of the removed tissue.^[10]

Recovery from lung cancer surgery typically takes several weeks. You may experience shortness of breath at first, especially with physical activity, and some discomfort around the incision site. Most patients gradually build up their strength and lung capacity over time. Walking regularly and following breathing exercises recommended by your healthcare team can help speed recovery and improve your breathing function.^[11]

Postoperative Adjuvant Chemotherapy

After surgery, most patients with stage II adenosquamous lung cancer receive adjuvant chemotherapy, which means chemotherapy given after the main treatment to reduce the risk of cancer returning. This additional treatment is particularly important for adenosquamous carcinoma because studies have shown it tends to be more aggressive than other types of lung cancer.^[1]

The standard chemotherapy approach uses platinum-based combinations, meaning one of the drugs contains platinum. The most commonly used combinations are cisplatin or carboplatin paired with another chemotherapy drug. For adenosquamous carcinoma, doctors often use carboplatin combined with either paclitaxel (also called Taxol) or gemcitabine. These drug combinations work by attacking both the adenocarcinoma and squamous cell carcinoma components of the tumor.^[8][11]

Treatment typically involves four cycles of chemotherapy, with each cycle usually spaced three weeks apart. This means the entire chemotherapy treatment lasts about three to four months. The drugs are given through an intravenous line, usually in an outpatient clinic, so you can go home the same day. Each infusion session may take several hours depending on the specific drugs used.^[1]

The purpose of this chemotherapy is to eliminate any cancer cells that might have spread beyond the area removed by surgery but are too small to detect with current imaging tests. Research has shown that platinum-based chemotherapy for at least four cycles can significantly improve survival in patients with stage II and III adenosquamous carcinoma.^[1]

Side Effects of Standard Treatment

Chemotherapy affects rapidly dividing cells throughout your body, not just cancer cells, which is why it causes side effects. Common side effects of platinum-based chemotherapy include nausea and vomiting, fatigue, loss of appetite, temporary hair loss, and increased risk of infections because the treatment temporarily lowers your white blood cell count. Carboplatin can also reduce your platelet count, which may increase bleeding or bruising.^[11]

Paclitaxel can cause numbness or tingling in your hands and feet, a condition called peripheral neuropathy. This usually improves after treatment ends but can sometimes persist. Gemcitabine may cause flu-like symptoms and can affect kidney function, so your doctor will monitor your blood tests regularly during treatment.^[11]

Your medical team can prescribe medications to help manage many of these side effects. Anti-nausea medications have improved dramatically in recent years, making chemotherapy much more tolerable than it was in the past. It’s important to report any side effects to your doctor promptly so they can help you manage them effectively. Sometimes, if side effects are severe, your doctor may adjust the dose or timing of your chemotherapy.^[11]

Treatment in Clinical Trials

Targeted Therapy Based on Genetic Mutations

One of the most promising developments in treating adenosquamous lung cancer involves testing the tumor for specific genetic changes, called driver mutations, that help the cancer grow. About 30% of adenosquamous carcinomas have mutations in a gene called EGFR (epidermal growth factor receptor), which can be targeted with specialized oral medications called tyrosine kinase inhibitors or TKIs.^[4]

If your tumor has an EGFR mutation, drugs like erlotinib, gefitinib, or dacomitinib can be effective treatment options, especially if the cancer returns after surgery or if you have advanced disease. These medications work by blocking the signals that tell cancer cells to grow and divide. They’re taken as pills at home rather than given through intravenous infusion, which many patients find more convenient than traditional chemotherapy.^[1]

A case report described a patient with stage IIIB adenosquamous carcinoma who was treated with dacomitinib as neoadjuvant therapy—treatment given before surgery to shrink the tumor. After eight weeks of treatment, the tumor had shrunk significantly, allowing for successful surgical removal. The final pathology showed no cancer in any lymph nodes, demonstrating how targeted therapy can sometimes make an inoperable tumor operable.^[10]

Another important targetable mutation found in about 5% of adenosquamous carcinomas involves the ALK gene (anaplastic lymphoma kinase). For patients with ALK-positive tumors, a drug called crizotinib can be used, though studies of this drug specifically in adenosquamous carcinoma are very limited. The mechanism works similarly to EGFR inhibitors—by blocking the abnormal protein that drives cancer growth.^[4]

It’s important to understand that these targeted therapies only work if your specific tumor has the matching genetic mutation. This is why comprehensive genetic testing of your tumor tissue is so important and is now considered standard practice for all patients with adenocarcinoma or adenosquamous carcinoma of the lung.^[4]

Immunotherapy: Training Your Immune System to Fight Cancer

Immunotherapy represents a major advance in cancer treatment over the past decade. These drugs don’t attack cancer cells directly. Instead, they help your own immune system recognize and destroy cancer cells. The most studied type of immunotherapy for lung cancer involves immune checkpoint inhibitors, which block proteins that prevent your immune cells from attacking cancer.^[1]

For immunotherapy to work best, doctors test your tumor for a protein called PD-L1 (programmed death-ligand 1). Research has found that in adenosquamous carcinoma, about 11% of the adenocarcinoma component and 28% of the squamous cell component express PD-L1. Higher PD-L1 expression generally means a better chance that immunotherapy will be effective.^[4]

While specific clinical trials of immunotherapy exclusively in stage II adenosquamous carcinoma are limited, the approach shows promise based on results in other types of non-small cell lung cancer. Immune checkpoint blockade therapy is considered a potential treatment choice for adenosquamous carcinoma patients, particularly those whose tumors show PD-L1 expression of 20% or higher.^[1][11]

The side effects of immunotherapy are different from those of chemotherapy. Because these drugs activate your immune system, they can sometimes cause your immune system to attack normal tissues in your body. This can lead to inflammation in various organs, including your lungs, intestines, liver, or thyroid gland. These side effects, called immune-related adverse events, need to be monitored carefully and treated promptly if they occur. However, many patients tolerate immunotherapy better than traditional chemotherapy.^[1]

Clinical Trial Phases and What They Mean

Clinical trials testing new treatments for adenosquamous lung cancer progress through several phases, each designed to answer specific questions about safety and effectiveness. Phase I trials primarily test whether a new treatment is safe and work to determine the best dose. These trials usually involve small numbers of patients, often those whose cancer hasn’t responded to standard treatments.^[1]

Phase II trials examine whether the treatment actually works against cancer. Researchers look at whether tumors shrink or stop growing, and they continue monitoring for side effects. These trials involve more patients than Phase I studies and begin to provide preliminary information about how well the treatment might work compared to existing options.^[1]

Phase III trials are large studies that directly compare a new treatment to the current standard treatment. These trials provide the strongest evidence about whether a new therapy should become a standard treatment option. If a Phase III trial shows that a new treatment is more effective or has fewer side effects than standard treatment, it may lead to approval by regulatory agencies like the FDA in the United States.^[1]

Clinical trials for lung cancer are conducted worldwide, including in the United States, Europe, and Asia. To participate in a trial, patients must meet specific eligibility criteria related to their cancer stage, previous treatments, overall health, and sometimes the genetic characteristics of their tumor. Your oncologist can help you determine whether there are appropriate clinical trials available for your situation.^[1]

Neoadjuvant Therapy: Treatment Before Surgery

An emerging approach in treating locally advanced lung cancer, including some stage II cases, involves giving treatment before surgery rather than after. This neoadjuvant approach aims to shrink the tumor, making surgery easier and more likely to remove all cancer. It may also eliminate cancer cells that have spread but aren’t yet visible on scans.^[10]

For adenosquamous carcinoma with EGFR mutations, neoadjuvant targeted therapy has shown promise in case reports. In one documented case, a patient received the targeted drug dacomitinib for eight weeks before surgery. The treatment successfully shrank the tumor and cleared cancer from the lymph nodes, allowing for complete surgical removal. After surgery, the patient received four cycles of standard chemotherapy and continued targeted therapy for a longer period.^[10]

The advantage of neoadjuvant therapy is that doctors can see how well the cancer responds to treatment. If the tumor shrinks significantly, it suggests the treatment is working and may help prevent recurrence. Research into neoadjuvant targeted therapy and immunotherapy for operable locally advanced non-small cell lung cancer is ongoing, with multiple clinical trials exploring these approaches.^[10]

Most Common Treatment Methods

• Surgical Resection
  • Lobectomy, which removes the entire lobe of the lung containing the cancer, is the standard surgical approach for stage II disease
  • Lymph node removal from the chest center helps determine exact cancer stage and whether additional treatment is needed
  • The goal is R0 resection with clear margins where no cancer cells remain at the tissue edges
• Platinum-Based Chemotherapy
  • Carboplatin or cisplatin combined with paclitaxel (Taxol) addresses both adenocarcinoma and squamous cell components
  • Gemcitabine paired with carboplatin is another effective combination used for adenosquamous carcinoma
  • Treatment typically consists of four cycles given every three weeks for three to four months total
  • Significantly improves survival when given after surgery in stage II and III patients
• Targeted Therapy
  • EGFR tyrosine kinase inhibitors including erlotinib, gefitinib, and dacomitinib for tumors with EGFR mutations
  • These oral medications block signals that tell cancer cells to grow and divide
  • About 30% of adenosquamous carcinomas have EGFR mutations that can be targeted
  • Crizotinib for the approximately 5% of tumors with ALK rearrangements
  • Can be used as neoadjuvant therapy before surgery to shrink tumors or as treatment for advanced disease
• Immunotherapy
  • Immune checkpoint inhibitors that help the immune system recognize and attack cancer cells
  • Effectiveness depends on PD-L1 expression levels in the tumor
  • PD-L1 is found in 11% of adenocarcinoma components and 28% of squamous cell components in adenosquamous carcinoma
  • Considered a potential treatment option particularly for tumors with 20% or higher PD-L1 expression